Skip to contentV
Vistagen Therapeutics, Inc.
V
VTGNVistagen Therapeutics, Inc. Q4 2019 · 10-K
Revenue—
Net Income-$5.72M-$5.72MN/M vs Q4 2018 EPS Diluted-$0.17-$0.17N/M vs Q4 2018 Operating Income-$5,722,000N/M Operating Cash Flowderived-$3,557,200N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Vistagen Therapeutics, Inc. · CIK 1411685 · Engraved from SEC EDGAR
Free Cash Flowderived-$3,731,200N/M ended Mar 31, 2019 · filed Jun 25, 2019 · 86 d after period end